Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Influenza

Free Subscription Articles published in Virology Retrieve available abstracts of 103 articles: HTML format

Single Articles

August 2022
1. ABDELKADER A, Elzemrany AA, El-Nadi M, Elsabbagh SA, et al
   In-Silico targeting of SARS-CoV-2 NSP6 for drug and natural products repurposing.
   Virology. 2022;573:96-110.
   PubMed     Abstract available
   
   
   
2. AL-ZYOUD W, Haddad H
   Potential linear B-cells epitope change to a helix structure in the spike of Omicron 21L or BA.2 predicts increased SARS-CoV-2 antibodies evasion.
   Virology. 2022;573:84-95.
   PubMed     Abstract available
   
   
   July 2022
3. WANG T, Wei F, Jiang Z, Song J, et al
   Influenza virus NS1 interacts with 14-3-3epsilon to antagonize the production of RIG-I-mediated type I interferons.
   Virology. 2022;574:47-56.
   PubMed     Abstract available
   
   
   
4. HAN M, Gao S, Hu W, Zhou Q, et al
   Inhibitory effects of cedar pine needle extract on H9N2 avian influenza virus in vitro and in vivo.
   Virology. 2022;574:25-36.
   PubMed     Abstract available
   
   
   
5. GE Y, Liu K, Chi Y, Zhu X, et al
   Exosomal microRNA expression profiles derived from A549 human lung cells in response to influenza A/H1N1pdm09 infection.
   Virology. 2022;574:9-17.
   PubMed     Abstract available
   
   
   
6. OH J, Subbiah J, Kim KH, Park BR, et al
   Impact of hemagglutination activity and M2e immunity on conferring protection against influenza viruses.
   Virology. 2022;574:37-46.
   PubMed     Abstract available
   
   
   
7. KUMAR P, Mathayan M, Smieszek SP, Przychodzen BP, et al
   Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection.
   Virology. 2022;572:64-71.
   PubMed     Abstract available
   
   
   
8. PONDE RAA
   Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern.
   Virology. 2022;572:44-54.
   PubMed     Abstract available
   
   
   June 2022
9. GUAN M, Jacobson O, Sarafianos G, Baroch J, et al
   Exposure of white-tailed deer in North America to influenza D virus.
   Virology. 2022;573:111-117.
   PubMed     Abstract available
   
   
   
10. LIM H, Kim SE, Lee YH, Hwang YH, et al
    Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein.
    Virology. 2022;573:118-123.
    PubMed     Abstract available
    
    
    
11. ZHU Y, Scholle F, Kisthardt SC, Xie DY, et al
    Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E.
    Virology. 2022;571:21-33.
    PubMed     Abstract available
    
    
    May 2022
12. KHAN K, Khan SA, Jalal K, Ul-Haq Z, et al
    Immunoinformatic approach for the construction of multi-epitopes vaccine against omicron COVID-19 variant.
    Virology. 2022;572:28-43.
    PubMed     Abstract available
    
    
    
13. ZMASEK CM, Lefkowitz EJ, Niewiadomska A, Scheuermann RH, et al
    Genomic evolution of the Coronaviridae family.
    Virology. 2022;570:123-133.
    PubMed     Abstract available
    
    
    
14. POPOVIC M
    Strain wars 2: Binding constants, enthalpies, entropies, Gibbs energies and rates of binding of SARS-CoV-2 variants.
    Virology. 2022;570:35-44.
    PubMed     Abstract available
    
    
    
15. EL-ASHREY MK, Bakr RO, Fayed MAA, Refaey RH, et al
    Pharmacophore based virtual screening for natural product database revealed possible inhibitors for SARS-COV-2 main protease.
    Virology. 2022;570:18-28.
    PubMed     Abstract available
    
    
    April 2022
16. PUCHINGER K, Castelletti N, Rubio-Acero R, Geldmacher C, et al
    The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 - Results from a prospective cohort of outpatient COVID-19 cases.
    Virology. 2022;569:37-43.
    PubMed     Abstract available
    
    
    
17. MI T, Wang T, Xu H, Sun P, et al
    Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants.
    Virology. 2022;569:56-63.
    PubMed     Abstract available
    
    
    
18. SARKAR L, Oko L, Gupta S, Bubak AN, et al
    Azadirachta indica A. Juss bark extract and its Nimbin isomers restrict beta-coronaviral infection and replication.
    Virology. 2022;569:13-28.
    PubMed     Abstract available
    
    
    
19. KAPCZYNSKI DR, Sweeney R, Spackman E, Pantin-Jackwood M, et al
    Development of an in vitro model for animal species susceptibility to SARS-CoV-2 replication based on expression of ACE2 and TMPRSS2 in avian cells.
    Virology. 2022;569:1-12.
    PubMed     Abstract available
    
    
    March 2022
20. MOGRO EG, Bottero D, Lozano MJ
    Analysis of SARS-CoV-2 synonymous codon usage evolution throughout the COVID-19 pandemic.
    Virology. 2022;568:56-71.
    PubMed     Abstract available
    
    
    
21. XU H, Akinyemi IA, Chitre SA, Loeb JC, et al
    SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway.
    Virology. 2022;568:13-22.
    PubMed     Abstract available
    
    
    February 2022
22. CHEN X, Sun HY, Lee CY, Rostad CA, et al
    Functional antibody-dependent cell mediated cytotoxicity (ADCC) responses to vaccine and circulating influenza strains following vaccination.
    Virology. 2022;569:44-55.
    PubMed     Abstract available
    
    
    January 2022
23. CHEN Z, Zeng Y, Wei Y, Wang Q, et al
    Influenza D virus Matrix protein 1 restricts the type I interferon response by degrading TRAF6.
    Virology. 2022;568:1-11.
    PubMed     Abstract available
    
    
    
24. AFRIN SZ, Islam MT, Paul SK, Kobayashi N, et al
    Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021.
    Virology. 2022;565:29-37.
    PubMed     Abstract available
    
    
    
25. SODERLUND-VENERMO M, Varma A, Guo D, Gladue DP, et al
    World Society for Virology first international conference: Tackling global virus epidemics.
    Virology. 2022;566:114-121.
    PubMed     Abstract available
    
    
    
26. NADERI N, Rahimzadeh M
    Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses.
    Virology. 2022;566:106-113.
    PubMed     Abstract available
    
    
    
27. RAYMONDA MH, Ciesla JH, Monaghan M, Leach J, et al
    Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
    Virology. 2022;566:60-68.
    PubMed     Abstract available
    
    
    
28. KUMAR P, Bhardwaj T, Garg N, Giri R, et al
    Microsecond simulations and CD spectroscopy reveals the intrinsically disordered nature of SARS-CoV-2 spike-C-terminal cytoplasmic tail (residues 1242-1273) in isolation.
    Virology. 2022;566:42-55.
    PubMed     Abstract available
    
    
    December 2021
29. PARK BR, Subbiah J, Kim KH, Kwon YM, et al
    Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.
    Virology. 2021;566:143-152.
    PubMed     Abstract available
    
    
    
30. HEINIMAKI S, Lampinen V, Tamminen K, Hankaniemi MM, et al
    Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology.
    Virology. 2021;566:89-97.
    PubMed     Abstract available
    
    
    
31. HU Z, Chen JP, Xu JC, Chen ZY, et al
    A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination.
    Virology. 2021;566:56-59.
    PubMed     Abstract available
    
    
    November 2021
32. TRIGUEIRO-LOURO J, Santos LA, Almeida F, Correia V, et al
    NS1 protein as a novel anti-influenza target: Map-and-mutate antiviral rationale reveals new putative druggable hot spots with an important role on viral replication.
    Virology. 2021;565:106-116.
    PubMed     Abstract available
    
    
    
33. GONG SY, Chatterjee D, Richard J, Prevost J, et al
    Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity.
    Virology. 2021;563:134-145.
    PubMed     Abstract available
    
    
    
34. RAI P, Chuong C, LeRoith T, Smyth JW, et al
    Adenovirus transduction to express human ACE2 causes obesity-specific morbidity in mice, impeding studies on the effect of host nutritional status on SARS-CoV-2 pathogenesis.
    Virology. 2021;563:98-106.
    PubMed     Abstract available
    
    
    
35. ABDELHAFIZ AS, Fouad MA, Sayed-Ahmed MM, Kamel MM, et al
    Upregulation of FOXP3 is associated with severity of hypoxia and poor outcomes in COVID-19 patients.
    Virology. 2021;563:74-81.
    PubMed     Abstract available
    
    
    
36. HARDER OE, Martinez M, Niewiesk S
    Nonsteroidal anti-inflammatory drugs restore immune function to respiratory syncytial virus in geriatric cotton rats (Sigmodon hispidus).
    Virology. 2021;563:28-37.
    PubMed     Abstract available
    
    
    October 2021
37. AHMED SM, Nasr MA, Elshenawy SE, Hussein AE, et al
    BCG vaccination and the risk of COVID 19: A possible correlation.
    Virology. 2021;565:73-81.
    PubMed     Abstract available
    
    
    
38. ZHANG G, Ng F, Chen M
    Short-hairpin RNAs delivered by recombinant adeno-associated virus inhibited the replication of influenza A viruses in vitro.
    Virology. 2021;564:46-52.
    PubMed     Abstract available
    
    
    
39. BYRD-LEOTIS L, Lasanajak Y, Bowen T, Baker K, et al
    SARS-CoV-2 and other coronaviruses bind to phosphorylated glycans from the human lung.
    Virology. 2021;562:142-148.
    PubMed     Abstract available
    
    
    
40. TAGHIZADEH P, Salehi S, Heshmati A, Houshmand SM, et al
    Study on SARS-CoV-2 strains in Iran reveals potential contribution of co-infection with and recombination between different strains to the emergence of new strains.
    Virology. 2021;562:63-73.
    PubMed     Abstract available
    
    
    
41. DEUTSCHMANN-OLEK KM, Yue WW, Bezerra GA, Skern T, et al
    Defining substrate selection by rhinoviral 2A proteinase through its crystal structure with the inhibitor zVAM.fmk.
    Virology. 2021;562:128-141.
    PubMed     Abstract available
    
    
    September 2021
42. WELCH M, Park J, Harmon K, Zhang J, et al
    Pathogenesis of a novel porcine parainfluenza virus type 1 isolate in conventional and colostrum deprived/caesarean derived pigs.
    Virology. 2021;563:88-97.
    PubMed     Abstract available
    
    
    
43. VERMA J, Subbarao N
    Insilico study on the effect of SARS-CoV-2 RBD hotspot mutants' interaction with ACE2 to understand the binding affinity and stability.
    Virology. 2021;561:107-116.
    PubMed     Abstract available
    
    
    
44. PLAAS M, Seppa K, Gaur N, Kasenomm P, et al
    Age- and airway disease related gene expression patterns of key SARS-CoV-2 entry factors in human nasal epithelia.
    Virology. 2021;561:65-68.
    PubMed     Abstract available
    
    
    August 2021
45. MENNE Z, Pliasas VC, Compans RW, Glover S, et al
    Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.
    Virology. 2021;562:197-208.
    PubMed     Abstract available
    
    
    
46. NAEMI FMA, Al-Adwani S, Al-Khatabi H, Al-Nazawi A, et al
    Frequency of HLA alleles among COVID-19 infected patients: Preliminary data from Saudi Arabia.
    Virology. 2021;560:1-7.
    PubMed     Abstract available
    
    
    July 2021
47. CHEN X, Rostad CA, Anderson LJ, Sun HY, et al
    The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein.
    Virology. 2021;559:1-9.
    PubMed     Abstract available
    
    
    June 2021
48. ICHIMIYA T, Okamatsu M, Kinoshita T, Kobayashi D, et al
    Sulfated glycans containing NeuAcalpha2-3Gal facilitate the propagation of human H1N1 influenza A viruses in eggs.
    Virology. 2021;562:29-39.
    PubMed     Abstract available
    
    
    
49. UEDA H, Yamakawa N, Takeuchi K
    Amino- and carboxyl-terminal ends of the bovine parainfluenza virus type 3 matrix protein are important for virion and virus-like particle release.
    Virology. 2021;561:17-27.
    PubMed     Abstract available
    
    
    
50. SUN H, Liu J, Xiao Y, Duan Y, et al
    Pathogenicity of novel reassortant Eurasian avian-like H1N1 influenza virus in pigs.
    Virology. 2021;561:28-35.
    PubMed     Abstract available
    
    
    
51. TERRY JS, Anderson LB, Scherman MS, McAlister CE, et al
    Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.
    Virology. 2021;558:28-37.
    PubMed     Abstract available
    
    
    
52. NAYAK K, Gottimukkala K, Kumar S, Reddy ES, et al
    Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India.
    Virology. 2021;558:13-21.
    PubMed     Abstract available
    
    
    May 2021
53. CASE JB, Winkler ES, Errico JM, Diamond MS, et al
    On the road to ending the COVID-19 pandemic: Are we there yet?
    Virology. 2021;557:70-85.
    PubMed     Abstract available
    
    
    
54. DJUKIC T, Mladenovic M, Stanic-Vucinic D, Radosavljevic J, et al
    Expression, purification and immunological characterization of recombinant nucleocapsid protein fragment from SARS-CoV-2.
    Virology. 2021;557:15-22.
    PubMed     Abstract available
    
    
    April 2021
55. UPRETY T, Sreenivasan CC, Bhattarai S, Wang D, et al
    Isolation and development of bovine primary respiratory cells as model to study influenza D virus infection.
    Virology. 2021;559:89-99.
    PubMed     Abstract available
    
    
    
56. WATERS K, Wan HJ, Han L, Xue J, et al
    Variations outside the conserved motifs of PB1 catalytic active site may affect replication efficiency of the RNP complex of influenza A virus.
    Virology. 2021;559:145-155.
    PubMed     Abstract available
    
    
    
57. NOLAN KE, Baer LA, Karekar P, Nelson AM, et al
    Metabolic shifts modulate lung injury caused by infection with H1N1 influenza A virus.
    Virology. 2021;559:111-119.
    PubMed     Abstract available
    
    
    
58. STAUFT CB, Lien CZ, Selvaraj P, Liu S, et al
    The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters.
    Virology. 2021;556:96-100.
    PubMed     Abstract available
    
    
    
59. DETSIKA MG, Ampelakiotou K, Grigoriou E, Psarra K, et al
    A novel ratio of CD8(+):B-cells as a prognostic marker of coronavirus disease 2019 patient progression and outcome.
    Virology. 2021;556:79-86.
    PubMed     Abstract available
    
    
    
60. ZHIRNOV OP, Chlanda P
    The cleavage of spike protein capital EN, Cyrilliccapital A, Cyrillic0-->capital EN, Cyrilliccapital A, Cyrillic1/HA2 by trypsin permits activation of the M2 channel without its proteolytic cleavage in the influenza A virus.
    Virology. 2021;559:86-88.
    PubMed     Abstract available
    
    
    March 2021
61. SEEKINGS AH, Warren CJ, Thomas SS, Mahmood S, et al
    Highly pathogenic avian influenza virus H5N6 (clade 2.3.4.4b) has a preferable host tropism for waterfowl reflected in its inefficient transmission to terrestrial poultry.
    Virology. 2021;559:74-85.
    PubMed     Abstract available
    
    
    
62. WOLF JJ, Xia C, Studstill CJ, Ngo H, et al
    Influenza A virus NS1 induces degradation of sphingosine 1-phosphate lyase to obstruct the host innate immune response.
    Virology. 2021;558:67-75.
    PubMed     Abstract available
    
    
    
63. XIE L, Yi K, Li Y
    SARS_CoV2 RBD gene transcription cannot be driven by CMV promoter.
    Virology. 2021;558:22-27.
    PubMed     Abstract available
    
    
    
64. LU KT, Yamamoto T, McDonald D, Li W, et al
    U.S.-Japan cooperative medical sciences program: 22nd International Conference on Emerging Infectious Diseases in the Pacific Rim.
    Virology. 2021;555:71-77.
    PubMed     Abstract available
    
    
    
65. TAKESHITA M, Nishina N, Moriyama S, Takahashi Y, et al
    Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan.
    Virology. 2021;555:35-43.
    PubMed     Abstract available
    
    
    February 2021
66. NOMURA N, Matsuno K, Shingai M, Ohno M, et al
    Updating the influenza virus library at Hokkaido University -It's potential for the use of pandemic vaccine strain candidates and diagnosis.
    Virology. 2021;557:55-61.
    PubMed     Abstract available
    
    
    
67. ABDEL-MONEIM AS, Abdelwhab EM, Memish ZA
    Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines.
    Virology. 2021;558:1-12.
    PubMed     Abstract available
    
    
    
68. ISHIGAKI H, Nakayama M, Kitagawa Y, Nguyen CT, et al
    Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques.
    Virology. 2021;554:97-105.
    PubMed     Abstract available
    
    
    
69. REFAEY RH, El-Ashrey MK, Nissan YM
    Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
    Virology. 2021;554:48-54.
    PubMed     Abstract available
    
    
    January 2021
70. FREIRE-PASPUEL B, Vega-Marino P, Velez A, Cruz M, et al
    Analytical and clinical comparison of Viasure (CerTest Biotec) and 2019-nCoV CDC (IDT) RT-qPCR kits for SARS-CoV2 diagnosis.
    Virology. 2021;553:154-156.
    PubMed     Abstract available
    
    
    December 2020
71. MORE SA, Patil AS, Sakle NS, Mokale SN, et al
    Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
    Virology. 2020;555:10-18.
    PubMed     Abstract available
    
    
    
72. LI L, Liang Y, Hu F, Yan H, et al
    Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients.
    Virology. 2020;551:26-35.
    PubMed     Abstract available
    
    
    
73. JIANG RD, Li B, Liu XL, Liu MQ, et al
    Bat mammalian orthoreoviruses cause severe pneumonia in mice.
    Virology. 2020;551:84-92.
    PubMed     Abstract available
    
    
    November 2020
74. YU R, Tan S, Dan Y, Lu Y, et al
    Effect of SARS-CoV-2 coinfection was not apparent on the dynamics of chronic hepatitis B infection.
    Virology. 2020;553:131-134.
    PubMed     Abstract available
    
    
    
75. POWELL JD, Abente EJ, Chang J, Souza CK, et al
    Characterization of contemporary 2010.1 H3N2 swine influenza A viruses circulating in United States pigs.
    Virology. 2020;553:94-101.
    PubMed     Abstract available
    
    
    
76. JONES LR, Manrique JM
    Quantitative phylogenomic evidence reveals a spatially structured SARS-CoV-2 diversity.
    Virology. 2020;550:70-77.
    PubMed     Abstract available
    
    
    
77. DOBROVOLNY HM
    Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.
    Virology. 2020;550:61-69.
    PubMed     Abstract available
    
    
    
78. KISHKO M, Catalan J, Swanson K, DiNapoli J, et al
    Evaluation of the respiratory syncytial virus G-directed neutralizing antibody response in the human airway epithelial cell model.
    Virology. 2020;550:21-26.
    PubMed     Abstract available
    
    
    October 2020
79. WU T, Ge Y, Zhao K, Zhu X, et al
    A reverse-transcription recombinase-aided amplification assay for the rapid detection of N gene of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).
    Virology. 2020;549:1-4.
    PubMed     Abstract available
    
    
    September 2020
80. NISSLY RH, Zaman N, Ibrahim PAS, McDaniel K, et al
    Influenza C and D viral load in cattle correlates with bovine respiratory disease (BRD): Emerging role of orthomyxoviruses in the pathogenesis of BRD.
    Virology. 2020;551:10-15.
    PubMed     Abstract available
    
    
    
81. SEYED HOSSEINI E, Riahi Kashani N, Nikzad H, Azadbakht J, et al
    The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies.
    Virology. 2020;551:1-9.
    PubMed     Abstract available
    
    
    
82. MOHTADI N, Ghaysouri A, Shirazi S, Sara Ansari, et al
    Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series.
    Virology. 2020;548:1-5.
    PubMed     Abstract available
    
    
    August 2020
83. KIM KH, Jung YJ, Lee Y, Park BR, et al
    Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.
    Virology. 2020;550:51-60.
    PubMed     Abstract available
    
    
    
84. ILYUSHINA NA, Lee N, Lugovtsev VY, Kan A, et al
    Adaptation of influenza B virus by serial passage in human airway epithelial cells.
    Virology. 2020;549:68-76.
    PubMed     Abstract available
    
    
    
85. NILSSON K, Abdurahman S, Schwartz S
    Influenza virus natural sequence heterogeneity in segment 8 affects interactions with cellular RNA-binding proteins and splicing efficiency.
    Virology. 2020;549:39-50.
    PubMed     Abstract available
    
    
    
86. JERRY C, Stallknecht D, Leyson C, Berghaus R, et al
    Recombinant hemagglutinin glycoproteins provide insight into binding to host cells by H5 influenza viruses in wild and domestic birds.
    Virology. 2020;550:8-20.
    PubMed     Abstract available
    
    
    
87. TANG J, Zhang SX, Zhang J, Li XY, et al
    Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.
    Virology. 2020;549:77-84.
    PubMed     Abstract available
    
    
    
88. MISHRA S, Goyal P, Kumar D, Chaudhari R, et al
    Experimental validation of influenza A virus matrix protein (M1) interaction with host cellular alpha enolase and pyruvate kinase.
    Virology. 2020;549:59-67.
    PubMed     Abstract available
    
    
    
89. ROTHAN HA, Stone S, Natekar J, Kumari P, et al
    The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.
    Virology. 2020;547:7-11.
    PubMed     Abstract available
    
    
    July 2020
90. SHI F, Wu T, Zhu X, Ge Y, et al
    Association of viral load with serum biomakers among COVID-19 cases.
    Virology. 2020;546:122-126.
    PubMed     Abstract available
    
    
    June 2020
91. WOODS PS, Doolittle LM, Rosas LE, Nana-Sinkam SP, et al
    Increased expression of microRNA-155-5p by alveolar type II cells contributes to development of lethal ARDS in H1N1 influenza A virus-infected mice.
    Virology. 2020;545:40-52.
    PubMed     Abstract available
    
    
    March 2020
92. LIU R, Sreenivasan C, Yu H, Sheng Z, et al
    Influenza D virus diverges from its related influenza C virus in the recognition of 9-O-acetylated N-acetyl- or N-glycolyl-neuraminic acid-containing glycan receptors.
    Virology. 2020;545:16-23.
    PubMed     Abstract available
    
    
    February 2020
93. FANG QQ, Huang WJ, Li XY, Cheng YH, et al
    Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice.
    Virology. 2020;545:1-9.
    PubMed     Abstract available
    
    
    
94. PURANIK A, Slomka MJ, Warren CJ, Thomas SS, et al
    Transmission dynamics between infected waterfowl and terrestrial poultry: Differences between the transmission and tropism of H5N8 highly pathogenic avian influenza virus (clade 2.3.4.4a) among ducks, chickens and turkeys.
    Virology. 2020;541:113-123.
    PubMed     Abstract available
    
    
    January 2020
95. MCALLISTER CS, Ansaldi D, Growcott EJ, Zhong Y, et al
    Dexamethasone inhibits respiratory syncytial virus-driven mucus production while increasing viral replication without altering antiviral interferon signaling.
    Virology. 2020;540:195-206.
    PubMed     Abstract available
    
    
    
96. LUDEKE B, Fearns R
    The respiratory syncytial virus polymerase can perform RNA synthesis with modified primers and nucleotide analogs.
    Virology. 2020;540:66-74.
    PubMed     Abstract available
    
    
    
97. ZOU S, Tang J, Zhang Y, Liu L, et al
    Molecular characterization of H3 subtype avian influenza viruses based on poultry-related environmental surveillance in China between 2014 and 2017.
    Virology. 2020;542:8-19.
    PubMed     Abstract available
    
    
    
98. STRAUS MR, Kinder JT, Segall M, Dutch RE, et al
    SPINT2 inhibits proteases involved in activation of both influenza viruses and metapneumoviruses.
    Virology. 2020;543:43-53.
    PubMed     Abstract available
    
    
    November 2019
99. LONDRIGAN SL, Wakim LM, Smith J, Haverkate AJ, et al
    IFITM3 and type I interferons are important for the control of influenza A virus replication in murine macrophages.
    Virology. 2019;540:17-22.
    PubMed     Abstract available
    
    
    
100. RODRIGUEZ P, Marcos-Villar L, Zamarreno N, Yanguez E, et al
     Mutations of the segment-specific nucleotides at the 3' end of influenza virus NS segment control viral replication.
     Virology. 2019;539:104-113.
     PubMed     Abstract available
     
     
     September 2019
101. YANG J, Xie D, Nie Z, Xu B, et al
     Inferring host roles in bayesian phylodynamics of global avian influenza A virus H9N2.
     Virology. 2019;538:86-96.
     PubMed     Abstract available
     
     
     August 2019
102. PATEL H, Kukol A
     Prediction of ligands to universally conserved binding sites of the influenza a virus nuclear export protein.
     Virology. 2019;537:97-103.
     PubMed     Abstract available
     
     
     May 2019
103. LEE Y, Ko EJ, Kim KH, Lee YT, et al
     A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.
     Virology. 2019;534:1-13.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: